TAG:
Esoteric testing
Esoteric testing allows the analysis of rare substances or molecules that are not performed in a routine clinical lab. Many large commercial lab companies outsource complex tests to reference and esoteric testing labs. However, as technology continues to expand laboratory testing, tests that are considered esoteric today may become routine in just a few years. This is often the result of work performed by dedicated research and development scientists.
These tests are ordered when a physician requires additional detailed information, outside routine lab testing, to complete a diagnosis, establish a prognosis or choose and monitor a therapeutic regimen. Esoteric testing generally requires sophisticated instruments and materials as well as specialized personnel to perform and analyze results. The tests are typically outsourced to independent, specialized clinical reference laboratories because it is not cost effective for hospitals and physician office laboratories to perform the tests in-house.
These tests are ordered less frequently than routine tests and are generally priced higher than the routine tests. Esoteric testing is typically related to the medical fields such as endocrinology, genetics, immunology, microbiology, molecular diagnostics, oncology, serology and toxicology. Molecular diagnostics is the fastest growing segment of esoteric clinical testing.
The American Chemical Society publishes the Directory of Rare Analyses (DORA) which catalogues rarely ordered clinical tests and provides details on the labs performing them.
The challenges for labs performing such tests include not only finding qualified medical technologists, but also paying them the higher salaries they command because of the scarcity of their skill sets. In addition, materials used in these tests can also be costly, particularly because they are not usually purchased in large enough quantities to qualify for economies of scale.
Labs that perform these tests have capabilities including:
• Allergy
• Complex anatomic pathology with board-certified pathologist
• Bone markers
• Genetic analysis
• HLA testing
• Functional assays of the immune system
• Toxicology
In the U.S., labs that perform these tests range from ARUP Laboratories, Mayo Medical Laboratories, Quest Diagnostics Incorporated, and Laboratory Corporation of America to a growing number of specialty esoteric testing laboratories that offer proprietary esoteric assays. Examples of such specialty testing lab companies include Myriad Genetics, Genomic Health, and Foundation Medicine.
Non-Pathologists Altering U.S. Laboratory Industry
By Robert Michel | From the Volume IX No. 13 – September 16, 2002 Issue
CEO SUMMARY: It’s an interesting contradiction. On one hand, most pathologists enthusiastically recognize the value that diagnostic testing services provide to the healthcare community. On the other hand, too often it is non-laboratorians who provide the investment capital and entrepren…
Changes Expected in Market For Hospital Reference Testing
By Robert Michel | From the Volume IX No. 13 – September 16, 2002 Issue
CEO SUMMARY: For the hospital send-out testing marketplace, 2002 has been an eventful year. First came the acquisition of American Medical Laboratories by Quest Diagnostics Incorporated. In April, Specialty Laboratories disclosed its problems with state and federal laboratory regulators. …
Specialty Laboratories’ New CEO Reveals How His Company Is Changing
By Robert Michel | From the Volume IX No. 11 – August 5, 2002 Issue
“You will see a more tightly focused Specialty Labs. We won’t try and do everything, rather we will do what is important for our customers.” —Douglas S. Harrington, M.D CEO SUMMARY: In recent months, several events roiled the market for hos…
Specialty Progresses With CA Lab Regulators
By Robert Michel | From the Volume IX No. 10 – July 15, 2002 Issue
CEO SUMMARY: Earlier this month California laboratory regulators found Specialty Laboratories, Inc. to be “in substantial compliance with California clinical laboratory law.” This is an important milestone in restoring the lab company to full compliance with both state and federal labor…
Specialty Lab’s Woes Trigger Big Market Shift
By R. Lewis Dark | From the Volume IX No. 9 – June 24, 2002 Issue
IT’S THE UNPUBLICIZED STORY BEHIND THE STORY. Most of the laboratory industry knows that Specialty Laboratories, Inc. is the target of sanctions issued by both federal and state laboratory regulators. But the impact of this development has yet to be recognized across the industry. …
Specialty Labs Struggles To Maintain Operations
By Robert Michel | From the Volume IX No. 9 – June 24, 2002 Issue
CEO SUMMARY: In April, Specialty Laboratories, Inc. disclosed that state and federal regulators had placed sanctions on the esoteric testing company, including revocation of its CLIA-88 license, subject to legal appeal. One main source of concern is the fact that, over the past 10 weeks, …
More Lab Consolidation: LabCorp Buys Dynacare
By Robert Michel | From the Volume IX No. 7 – May 13, 2002 Issue
CEO SUMMARY: Recent weeks brought many rumors about an impending deal between Laboratory Corporation of America and Dynacare. That speculation was ended last week when it was disclosed that LabCorp would pay about $685 million in cash, stock and assumed debt to acquire Dynacare. The acqui…
High Cost of New Assays Stretching Lab Budgets
By Robert Michel | From the Volume IX No. 7 – May 13, 2002 Issue
CEO SUMMARY: Growing numbers of hospital labs report that higher costs of new diagnostic tests have become a new management problem. That’s because diagnostic manufacturers are developing tests around a new business model, one that calls for higher pricing based on a premise of higher c…
State, Federal Regulators Target Specialty Labs
By Robert Michel | From the Volume IX No. 6 – April 22, 2002 Issue
CEO SUMMARY: Specialty Laboratories, Inc. has earned the dubious honor of being the first-ever publicly-traded laboratory to have its CLIA-88 license revoked by federal regulators, terminating its right to payment for services covered by Medicare and Medicaid. The revocation is slated to …
Quest Pays $1.1 Billion To Acquire Unilab Corp.
By Robert Michel | From the Volume IX No. 6 – April 22, 2002 Issue
CEO SUMMARY: Quest Diagnostics Incorporated is showing its muscle. The dust had hardly settled on its $500 million acquisition of American Medical Laboratories when the lab industry’s behemoth announced that it would pay $1.1 billion to buy Unilab, by far the largest lab testing company…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized